Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide. Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Shares of medication company Viatris (NASDAQ:VTRS)
jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer® Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer®, a drug with annual U.S. sales of approximately $515 million. Crucially, the U.S. Food and Drug Administration (FDA) also granted Viatris a Competitive Generic Therapy (CGT) designation for two strengths of the drug. This designation provides Viatris with 180 days of market exclusivity, giving the company a significant first-mover advantage to capture market share for this complex-to-manufacture product.
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be around $13.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.62 per share was 11.6% above analysts’ consensus estimates.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of medication company Viatris (NASDAQ:VTRS)
fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with Viatris (NASDAQ:VTRS).
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drawdown was discouraging since the S&P 500 held its ground.
Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3% above analysts’ consensus estimates.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of healthcare and pharmaceutical products.”
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
